Posted on November 9, 2009 by Sitemaster
Most prostate cancer activists (and certainly those on the West Coast) will want to be aware of an “OpEd” into today’s issue of the San Francisco Chronicle. The OpEd says it is by Laura Esserman, MD, but the credits suggest that actually it is by Dr. Esserman in conjunction with Ian Thompson, MD, the co-authors of a recent review on controversies related to prostate and breast cancer screening and related actions.
The “New” Prostate Cancer InfoLink is in complete agreement with the authors when they state categorically that, “We are not proposing that we stop all screening; we are saying that we can and must do better.”
Filed under: Diagnosis, Risk | Leave a Comment »
Posted on November 8, 2009 by Sitemaster
This weekend’s news report includes items on:
- Numbers of biopsy cores and accuracy of diagnosis for focal therapy
- Early data from the Prostate Cancer Research International: Active Surveillance (PRIAS) study
- Ultrasensitive PSA testing and risk of progression following radical prostatectomy … READ MORE …
Filed under: Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active surviellance, biopsy, cores, focal therapy, progression, PSA, radical prostatectomy, ultrasensitive | Leave a Comment »
Posted on November 7, 2009 by Sitemaster
The evidence supporting a role for the combination of dutasteride with ketoconazole as a form of second- or third-line hormone therapy for patients with castration-resistant prostate cancer (CRPC) appears to be increasing. … READ MORE …
Filed under: Management, Treatment, Uncategorized | Tagged: castration-resistant prostate cancer, CRPC, dutasteride, ketoconazole | 1 Comment »
Posted on November 6, 2009 by Sitemaster
Data presented last Monday at the annual meeting of the American Society for Radiation Oncology (ASTRO) suggest a possible role of anticoagulant therapy (using drugs like aspirin, warfarin, or clopidogrel/Plavix) in combination with radiation for the treatment of localized prostate cancer. … READ MORE …
Filed under: Management, Treatment | Tagged: anticoagulant, aspirin, clopidogrel, radiation, warfarin | Leave a Comment »
Posted on November 6, 2009 by Sitemaster
In today’s news reports from sources other than the ASTRO meeting, we note items dealing with:
- PSA bounce in brachytherapy patients
- Fatal prostate cancer and a history of smoking
- Ketoconazole + dutasteride in treatment of CRPC … READ MORE …
Filed under: Management, Prevention, Risk, Treatment | Tagged: Avodart, brachytherapy, castration-resistant prostate cancer, CRPC, dutasteride, ketoconazole, PSA bounce, smoking | 1 Comment »
Posted on November 5, 2009 by Sitemaster
Other news reports today — from sources not related to the ASTRO annual meeting — address such topics as:
- Perceptions about the US Preventive Services Task Force recommendations regarding the use of PSA testing men men > 75 years
- Renal insufficiency in men of long-term drug therapy for prostate cancer
- Cetuximab + doxirubicin in the treatment of CRPC
- The mechanism of action of estrogens in treatment of advanced prostate cancer … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: cetruximab, doxirubicin, estrogen, PSA testing, renal in sufficiency, USPSTF | Leave a Comment »
Posted on November 5, 2009 by Sitemaster
Two new studies reported at the American Society for Radiation Oncology (ASTRO) annual meeting yesterday discuss the potential of shorter courses of “hypofractionated” radiation therapy in the treatment of localized prostate cancer. … READ MORE …
Filed under: Management, Treatment | Tagged: hypofractionated, outcome, radiation, risk | 1 Comment »
Posted on November 5, 2009 by Sitemaster
Based on retrospective analysis of 2,132 prostate cancer patients in their single-institution database, researchers from the Fox Chase Cancer Center have reported that patients receiving radiation as first-line treatment for localized prostate cancer and who have a rising PSA within 18 months are at a significantly increased risk of death from prostate cancer compared to those whose PSA starts to rise after > 18 months. … READ MORE …
Filed under: Management, Treatment | Tagged: biochemical failure, PSA, radiation | Leave a Comment »
Posted on November 4, 2009 by Sitemaster
“Evidence continues to mount that the use of statins is inversely correlated with the risk of [high grade] prostate cancer,” says Elizabeth Platz, co-director of the cancer prevention and control program at the Johns Hopkins Kimmel Cancer Center, who is quoted in a report on the HealthDay web site. … READ MORE …
Filed under: Diagnosis, Prevention, Risk | Tagged: Prevention, risk, statins | Leave a Comment »
Posted on November 4, 2009 by Sitemaster
Two papers presented at the annual meeting of the American Society for Radiation Oncology (ASTRO) offer some further information on the application of proton beam radiation therapy (PBRT) in treatment of prostate cancer. … READ MORE …
Filed under: Management, Treatment | Tagged: PBRT, proton beam radiation therapy | Leave a Comment »
Posted on November 4, 2009 by Sitemaster
Posted on November 3, 2009 by Sitemaster
A report presented yesterday in Chicago, at the annual meeting of the American Society for Radiation Oncology (ASTRO), suggests that short-term hormone therapy given prior to and during first-line radiation treatment to intermediate-risk prostate cancer patients increases their chance of living longer, compared to those who receive radiation alone. However, the same study also showed that there is no significant benefit for low-risk patients. … READ MORE …
Filed under: Management, Treatment | Tagged: first line, hormone therapy, localized, radiation, RTOG 94-08 | Leave a Comment »
Posted on November 3, 2009 by Sitemaster
The precision with which external beam radiation can be delivered to specific areas of the spine is recognized as being critical to the effectiveness and safety of this treatment for spinal cancer metastases, which are a common problem with progressive prostate cancer. … READ MORE …
Filed under: Management, Treatment | Tagged: IGRT, image-guided radiation therapy, metastasis, spine | 1 Comment »
Posted on November 2, 2009 by Sitemaster
In August this year, Vis and Schröder published the first of two summary reviews on the key targets of hormonal treatment of prostate cancer. The second of these two key reviews has now appeared in the November issue of BJU International. … READ MORE …
Filed under: Management, Treatment, Uncategorized | Tagged: 5-ARIs, 5α-reductase inhibitor | 11 Comments »
Posted on November 2, 2009 by Sitemaster
Earlier this year, Dendreon stated that the company expected to file a revised Biologics License Application (BLA) for sipuleucel-T (Provenge) by mid-November. The company reported today that filing of the revised BLA is now complete. … READ MORE …
Filed under: Drugs in development, Uncategorized | Tagged: Provenge, sipuleucel-T | Leave a Comment »
SUPPORT 
Search for new and
ongoing trials on the
CTAG PCa web site
